FDA Updates DSCSA Waiver Framework With Small Business Exemption

A new FDA exemption issued 6 August 2026 for small business dispensers under Section 582 of the FD&C Act signals that manufacturers and trading partners need to reassess their DSCSA compliance posture, particularly around product tracing obligations and authorized trading partner verification. The exemption follows a pattern of targeted regulatory relief that the agency has deployed since the DSCSA enforcement baseline was established.

Under the DSCSA framework, FDA holds authority to grant three distinct forms of relief: waivers, exceptions, and exemptions. Each carries a different eligibility threshold. A waiver is available to any authorized trading partner facing undue economic hardship or emergency medical circumstances, including a declared public health emergency under Section 319 of the Public Health Service Act. An exception applies narrowly to manufacturers and repackagers when container size physically prevents accommodation of a compliant product identifier label. An exemption covers a broader set of products or transactions where relief is necessary to maintain public health or is otherwise appropriate under Section 582.

For regulatory affairs leads, the submission pathway is determinative. CDER-regulated products must route all waiver, exception, and exemption requests through CDER NextGen. CBER-regulated products tied to a BLA, NDA, or ANDA require eCTD-format submission via FDA's Electronic Submissions Gateway as product correspondence. Requests not associated with an application should be directed to [email protected]. Misrouting a submission risks processing delays that could leave a trading partner out of compliance during the review period.

FDA also retains authority to initiate exceptions and exemptions independently, without a stakeholder petition, under Sections 582(a)(3)(A)(ii) and (iii) of the FD&C Act. When the agency acts on its own initiative, it notifies affected trading partners in writing or through a public announcement. Agency-initiated relief may be time-limited or remain valid until further notice, a distinction that QA directors should track closely given the precedent set by the COVID-19 product exemption issued in May 2023, which expired at the close of the public health emergency.

The 8 August 2026 small business dispenser exemption is the most recent in a sequence that includes the October 2024 exemption covering certain trading partners under Section 582(g)(1) and the June 2024 small dispenser exemption updated with clarifying language in July 2024. Each iteration has refined the agency's interpretation of what constitutes appropriate relief, and the cumulative record now provides a substantive reference base for any manufacturer evaluating whether to file a request.

Manufacturers supplying small business dispensers should confirm whether their downstream partners qualify under the August 2026 exemption before the next scheduled product tracing audit cycle.

Source: FDA Drugs RSS Feed via FDA.gov, 24 August 2026.